Amgen, Horizon Blast FTC's 'Speculation On Speculation'
Amgen and Horizon Therapeutics insisted that the Federal Trade Commission's challenge to their merger is undone by real-world market dynamics that make it impractical to bundle products that, as the agency...To view the full article, register now.
Already a subscriber? Click here to view full article